In situ forming gel (ISG) is relevant for periodontal pocket drug delivery because of its local administration with sustained drug release. Various types of 25% w/w Eudragit®-based ISG in different solvents were prepared for 5% w/w doxycycline hyclate (DH) loading. All Eudragit® types could be dissolved by N-methyl-2-pyrrolidone (NMP), and Eudragit® RL and RS are mostly dissolved in various types of solvent. Except for Eudragit® E, the 5% w/w DH-loaded Eudragit® solutions using NMP as the solvent transformed into gel state or matrix-like after exposure to phosphate buffer pH 6.8 and efficiently sustained a drug release. Eudragit® L ISG in NMP achieved a sustained drug release for longer than 7 days. Viscosity and injectability were increased as the concentration of Eudragit® L increased. The 15%, 20% and 25% w/w Eudragit® L exhibited up to 52%, 48% and 42% drug released at 7 days. The drug release kinetic of DH-loaded in Eudragit® L mostly conformed with Higuchi's kinetics with Fickian diffusion. Their degradation rate was decreased as Eudragit® L concentration increased meanwhile denser scaffolds structure was evident. In addition, Staphylococcus aureus, Escherichia coli, and the major pathogen of periodontitis, i.e., Porphyromonas gingivalis, were efficiently inhibited. Thus, DH-loaded Eudragit® L ISG using NMP as a solvent showed potential as the periodontal pocket delivery of DH for periodontitis treatment.
留言 (0)